EFFICACY, GROWTH, AND SAFETY OUTCOMES OF TEDUGLUTIDE IN CHILDREN WITH SHORT BOWEL SYNDROME–ASSOCIATED INTESTINAL FAILURE (SBS–IF): A PHASE 3 STUDY. Samuel Kocoshis1, Beth Carter2,
Susan Hill3, Simon Horslen4, Stuart Kaufman5, David Mercer6, Russell Merritt7, Mikko Pakarinen8, Susan Protheroe9, Robert Venick10, Paul W. Wales11, Simin Hu12, Andrew Grimm12. 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 2Children’s Hospital of Los Angeles, Keck USC School of Medicine, Los Angeles, CA, USA; 3Great Ormond Street Hospital for Children, London, United Kingdom; 4Seattle Children’s Hospital and University of Washington School of Medicine, Seattle, WA, USA; 5MedStar Georgetown Transplant Institute and Georgetown University School of Medicine, Washington, , USA; 6Nebraska Medical Center, Omaha, NE, USA; 7Children’s Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; 8Children’s Hospital, Helsinki University Central Hospital, Helsinki, Finland; 9Birmingham Women’s and Children’s Hospital NHS Trust, Birmingham, United Kingdom; 10Mattel Children’s Hospital UCLA, Los Angeles, CA, USA; 11The Hospital for Sick Children, Toronto, ON, Canada; 12Shire Human Genetic Therapies, Inc., Lexington, MA, USA.